Immunosuppressive Agents
Immunosuppressive Agents - Related Videos
08:38
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
0 Views •
Cited by 28 •
2015
Here we describe a high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay to quantify the immunosuppressant tacrolimus in dried blood spots using a simple manual protein precipitation step and online column extraction.
11:27
Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging
0 Views •
Cited by 5 •
2016
This protocol describes the preparation and characterization of a dendrimeric magnetic resonance imaging (MRI) contrast agent that carries cyclen-based macrocyclic chelates coordinating paramagnetic gadolinium ions. In a series of MRI experiments in vitro, this agent produced an amplified MRI signal when compared to the commercially available monomeric analogue.
10:19
Reducing Agents
0 Views •
2023
Source: Vy M. Dong and Daniel Kim, Department of Chemistry, University of California, Irvine, CA Controlling the reactivity and selectivity during the synthesis of a molecule is very important criteria for chemists. This has led to the development of many reagents that allow chemists to pick and choose reagents suitable for a given task. Quite often, a balance between reactivity and selectivity needs to be achieved. This experiment will use IR spectroscopy to monitor the reaction and to...
07:40
Introducing Experimental Agents into the Mouse
0 Views •
2023
Many investigations performed in mice (Mus musculus) require the administration of an experimental agent to the animal. For example, it may be of interest to test the efficacy of a specific therapy, to induce a pathologic condition, or to administer anesthesia or palliative care. In order to ensure safe and efficient delivery, it is important to consider a variety of factors prior to the administration of the treatment. This video, which reviews agent administration in the mouse, begins by...
09:25
Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations
0 Views •
Cited by 7 •
2015
Using optimized human peripheral blood mononuclear cell (PBMC) ex vivo assays, we showed that a combustible tobacco product preparation markedly suppresses receptor-mediated intracellularly secreted cytokines and cytolytic ability of effector PBMCs. These rapid assays may be useful in product evaluation and understanding the potential long-term effects of tobacco exposure.
FAQs
These agents can interrupt signaling between immune cells, reduce lymphocyte activation, or limit lymphocyte proliferation. They may also decrease the production or action of inflammatory mediators, which are substances that promote inflammation. Because these mechanisms affect different stages of immune responses, their biological effects can include reduced harmful inflammation and weaker immune reactions against transplanted tissues or the body’s own cells.
Lymphocyte activation and proliferation expand immune responses and help sustain attacks against recognized targets. Restricting these processes can reduce reactions directed toward transplanted tissues or the body’s own cells. This mechanism therefore connects cellular regulation with outcomes such as improved graft survival and better control of autoimmune or inflammatory disease, although the extent of suppression influences the overall biological consequences.
Blocking immune-cell signaling acts on communication that helps coordinate immune responses, whereas reducing inflammatory mediators limits substances that produce or maintain inflammation. These mechanisms target related but distinct parts of immune regulation. Their distinction is useful when interpreting how an agent may control inflammation, cellular immune activity, or both, rather than treating all immunosuppressive effects as biologically identical.
The desired effect is sufficient suppression to control harmful inflammation, autoimmune activity, or rejection of transplanted tissue. Excessive suppression can increase susceptibility to infection because normal immune defenses are also weakened. This trade-off makes long-term treatment decisions complex: disease control and graft survival must be considered alongside the consequences of reducing protective immune-system activity.
In transplantation, these agents support the survival of organs or tissues by reducing immune responses directed against the graft. In autoimmune disorders, they help limit responses against the body’s own cells. They also have applications in inflammatory disorders, where reducing inflammatory mediators or immune-cell activity can improve control of harmful inflammation.
Studies can examine whether an agent reduces immune-cell signaling, lymphocyte activation or proliferation, or the production and action of inflammatory mediators. Researchers can then relate those changes to broader outcomes, including control of inflammation, protection of transplanted tissues, and altered immune regulation. Susceptibility to infection also represents an important consequence of excessive immune suppression.
These compounds provide biological tools for examining how immune responses are coordinated and restrained. By reducing signaling, lymphocyte activity, or inflammatory mediator action, they help researchers connect specific immune processes with outcomes in transplantation, autoimmune disease, and inflammation. Their effects also reveal the importance of balancing immune protection against harmful or excessive immune activity.